» Articles » PMID: 27904785

Overexpression of YWHAZ As an Independent Prognostic Factor in Adenocarcinoma of the Esophago-gastric Junction

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2016 Dec 2
PMID 27904785
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Several studies have demonstrated that YWHAZ (14-3-3ζ), included in the 14-3-3 family of proteins, is implicated in the initiation and progression of cancers. To detect a novel treatment target for adenocarcinoma of the esophagogastric junction (AEG), we tested whether YWHAZ acted as a cancer-promoting gene through its overexpression in AEG. We analyzed YWHAZ protein expression in 92 consecutive primary AEG tumors, which had been curatively resected in our institution between 2000 and 2010. Overexpression of the YWHAZ protein was frequently detected in primary AEG tumor samples (46% (42/92)). Overexpression of YWHAZ was significantly correlated with Siewert type III tumor, larger tumor size (≥40 mm) and higher rates of lymph node metastasis and recurrence. Patients with YWHAZ-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors ( = 0.011, log-rank test) in an intensity expression-dependent manner. Patients with YWHAZ-overexpression tumors had worse overall survival rates than those with lower-expression tumors. YWHAZ positivity was independently associated with a worse outcome in the multivariate analysis ( = 0.0015, hazard ratio 4.49 [1.736-13.06]). In conclusion, YWHAZ plays a crucial role in poor outcomes of patients with AEG through its overexpression, which highlights its usefulness as a prognosticator and potential therapeutic target and indicator in AEG.

Citing Articles

Pediatric fibromyxoid brachial plexus tumor with YWHAZ::PLAG1 gene fusion: a case report.

Cua S, Odono E, Chan K, Casanova D, Guerzon A, Khu K Childs Nerv Syst. 2024; 40(6):1919-1924.

PMID: 38459146 DOI: 10.1007/s00381-024-06359-y.


A Computational Approach to Justifying Stratifin as a Candidate Diagnostic and Prognostic Biomarker for Pancreatic Cancer.

Mogal M, Junayed A, Mahmod M, Sompa S, Lima S, Kar N Biomed Res Int. 2022; 2022:1617989.

PMID: 35547358 PMC: 9085308. DOI: 10.1155/2022/1617989.


hsa-MicroRNA-28-5p Inhibits Diffuse Large B-Cell Lymphoma Cell Proliferation by Downregulating 14-3-3 Expression.

Yan S, Chen Y, Yang M, Zhang Q, Ma J, Liu B Evid Based Complement Alternat Med. 2022; 2022:4605329.

PMID: 35027933 PMC: 8752235. DOI: 10.1155/2022/4605329.


YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis.

Zhang T, Beeharry M, Wang Z, Zhu Z, Li J, Li C Int J Biol Sci. 2021; 17(7):1629-1643.

PMID: 33994849 PMC: 8120461. DOI: 10.7150/ijbs.58921.


HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma.

Wang Z, Xiao W, Jiang Y, Dong W, Zhang X, Zhang L Thorac Cancer. 2021; 12(5):650-658.

PMID: 33471419 PMC: 7919121. DOI: 10.1111/1759-7714.13842.


References
1.
Naoi Y, Miyoshi Y, Taguchi T, Kim S, Arai T, Maruyama N . Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. Cancer Lett. 2008; 262(2):248-56. DOI: 10.1016/j.canlet.2007.12.008. View

2.
Sharma R, Samantaray S, Shukla N, Ralhan R . Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics. 2003; 81(5):481-8. DOI: 10.1016/s0888-7543(03)00023-5. View

3.
Clemons N, Phillips W, Lord R . Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther. 2013; 14(9):782-95. PMC: 3909547. DOI: 10.4161/cbt.25362. View

4.
Frasor J, Chang E, Komm B, Lin C, Vega V, Liu E . Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006; 66(14):7334-40. DOI: 10.1158/0008-5472.CAN-05-4269. View

5.
Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C . Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology. 2014; 61(3):930-41. PMC: 4450343. DOI: 10.1002/hep.27492. View